GW & Wade’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

GW & Wade’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$13K	Hold	545	–	–	﹤0.01%	417
2023 Q3	$11K	Hold	545	–	–	﹤0.01%	400
2023 Q2	$14K	Hold	545	–	–	﹤0.01%	382
2023 Q1	$11K	Buy	+545	New	+$12.2K	﹤0.01%	373

Other funds holding VINC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

GW & Wade's VINC Position: Q4 2023 in Review

GW & Wade held its Vincerx Pharma, Inc. Common Stock (VINC) position steady in Q4 2023 at 545 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #417.

GW & Wade first reported a position in VINC in Q1 2023 and has held it in 4 quarters since. The position peaked at $14K in Q2 2023. 32 funds tracked by Wall St. Rank hold VINC as of Q4 2023.

GW & Wade held 545 shares of Vincerx Pharma, Inc. Common Stock worth $13K as of Q4 2023.
GW & Wade left its Vincerx Pharma, Inc. Common Stock share count unchanged in Q4 2023.
Vincerx Pharma, Inc. Common Stock made up ﹤0.01% of GW & Wade's portfolio in Q4 2023, its #417 holding.
GW & Wade first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2023 and has held it in 4 quarters since.
GW & Wade's Vincerx Pharma, Inc. Common Stock position peaked at $14K in Q2 2023.
32 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2023.

Based on GW & Wade's 13F filing for Q4 2023, filed 8 Feb 2024.